Meet the Scientist - Paola Picardi (Axxam)

Meet the Scientist - Paola Picardi (Axxam)

 

Paola Picardi, Ph.D.
Scientist, Cell Biology

Axxam SpA
Openzone – Via Meucci 3
Bresso, Italy

 


Can you explain your research within PHAGO in 2 sentences?

Development of cell-based assay for TREM2 and CD33, suitable for High Throughput Screening (HTS) purpose and the adaptation to HTS platform of cell-based assay generated by partners.

What do your friends and family think what you are doing in the lab?
My friends think that I have fun with the cells (not well identified material). My family thinks I am stressed by the cells (not well identified material).

What are you really doing? (What’s your favourite task to do in the lab?)
I generated an innovative cell-based assay to validate TREM2 agonists and I tested all the quality criteria required by industry-standards (robustness, reproducibility, signal stability). Therefore, the assay is suitable for compound testing in industrial settings, aimed to the identification of pharmacological tool compounds for the treatment of Alzheimer Disease.

Why are you interested in Alzheimer’s Disease?
AD is a growing epidemic across the globe and the identification of suitable therapeutic approaches represents one of the greatest medical challenges.

What is the major challenge in Alzheimer research for you?
The identification of effective treatments having into account the multifactorial nature of the disease.

Trem2 or CD33?
Trem2

Coffee or Tea?
Coffee

Why does your research matter to the average citizen/man on the street?

AD is the most common dementia in the elderly and the world’s population is ageing.

The must-follow science twitter account?
I do not use twitter.

The must-read article on Alzheimer research?

"TREM2 lipid sensing sustains microglia response in an Alzheimer’s disease model”  (Cell. 2015 Mar 12;160(6):1061-71.)


What else do you like to read (except research articles)?

Novels

Your most surprising research finding?
The genetic and pharmacological inactivation of cannabinoid CB1 receptor is able to inhibit angiogenesis.

What is your personal highlight in PHAGO up to now?
The generation of a robust assay for TREM2 activation already used to run a screening activity that identified a specific TREM2 agonist.

What’s your favourite thing to do outside the lab?
To go to the theatre.

Best recent TV series/movie/novel depicting scientists?
Dr House

Prof. Harald Neumann
Prof. Harald Neumann
Prof. Jochen Walter
Prof. Jochen Walter
Prof. Guy Brown
Prof. Guy Brown
Dr Oliver Cousins
Dr Oliver Cousins
Tamara Raschka
Tamara Raschka
Mara Tornincasa
Mara Tornincasa
Paola Picardi
Paola Picardi
Dr Mona Mathews
Dr Mona Mathews
Home
Menu
Top
 

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115976. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA companies.

Social Media

PHAGO by Twitter PHAGO by LinkedIn

This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115976. This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and EFPIA companies.